(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.

Indian Pharmaceuticals Market continued to report mid-single digit growth on year on year basis in October. IPM sales grew by ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

With the respiratory illness season starting up in earnest, Vicks has reclaimed the top Rx and over-the-counter (OTC) pharma ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

The FTSE 100 index slumped 99.42 points, 1.2%, at 8,025.77. The FTSE 250 closed down 295.73 points, 1.4%, at 20,427.80. The AIM All-Share fell 7.07 points, 1.0%, at 730.86.

GSK celebrates 100 years in India with former MDs, highlighting resilience and reinvention in the pharmaceutical industry.

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

“HR has to be very agile, but also very smart in understanding what employees want and being able to provide that within your ...

When Hurricane Helene damaged western North Carolina in September, filling medical facilities with people who couldn’t be ...